MA-NITTO-DENKO
31.3.2021 13:02:14 CEST | Business Wire | Press release
In response to the rapid market expansion of oligonucleotide therapeutics that have potential to treat both common and intractable diseases, Nitto Denko Corporation (Headquarters: Osaka; President: Hideo Takasaki; referred to hereafter as “Nitto”) will invest approximately 25 billion Japanese yen in Nitto Denko Avecia Inc. (Headquarters: Massachusetts, USA; referred to hereafter as “Avecia”), a subsidiary of Nitto, and other related business establishments and group companies. This investment will significantly increase the manufacturing capacity of its oligonucleotide therapeutic business.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210331005336/en/
In addition to the already existing clinical development centered around rare diseases, development of oligonucleotide therapeutics for common diseases and intractable diseases such as cancer is progressing towards commercialization.
Since the acquisition of Avecia in 2011, Nitto has continued to invest in resources in order to provide comprehensive value in raw material manufacturing, contract manufacturing of the drug substance, final formulation, contract manufacturing of drug product and analytical services. In doing so, Nitto has contributed to the growth of the oligonucleotide therapeutic market.
At Avecia headquarters in Milford MA, Avecia is expanding process and analytical development of oligonucleotide therapeutic manufacturing based on its experience in handling more than 1,200 oligonucleotide sequences to enhance its quick and reliable manufacturing process design services. Furthermore, Avecia will establish a new building and production line for commercial manufacturing of the drug substance in order to secure sufficient supply for commercial scales. The process development building is scheduled to start operations in 2021 and the commercial manufacturing building and production line are scheduled to start operations in early 2023.
Future plans include another 25 billion Japanese yen investment to further increase the supply capacity of the polymer support used for oligonucleotide therapeutic manufacturing and expand the production line of oligonucleotide therapeutics for early clinical scales.
As a manufacturer of high-performance materials, Nitto aims to realize a better society and environment through the development of new products and new functions under its brand slogan, “Innovation for Customers”. By strengthening its capacity, Nitto can seamlessly handle manufacturing from initial stages of development to commercial scales. This will allow Nitto to support the rapidly growing oligonucleotide therapeutic market and contribute to creating a safe and healthy society.
About NITTO DENKO AVECIA INC.
Nitto Denko Avecia Inc. is a leader in oligonucleotide therapeutic manufacturing and development services with facilities located in Milford (Massachusetts) and Cincinnati (Ohio). Services for DNA and RNA-based therapeutics are provided from milligram to commercial scale. For more information, please visit www.Avecia.com .
About Oligonucleotide Therapeutics
Oligonucleotide therapeutics are comprised of nucleic acids such as DNA and RNA and are considered to be the next generation of pharmaceuticals following antibody therapeutics. Due to their direct effect on gene expression, oligonucleotide therapeutics may prove to be a revolutionary medicine that enables the treatment of illnesses that were previously difficult to treat. As a result, development towards commercialization is gaining momentum.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210331005336/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Aesthetics® Announces EU Approval of Two New Indications for Their Hyaluronic Acid Filler BELOTERO® Balance30.3.2026 22:49:00 CEST | Press release
Merz Aesthetics®, the world’s largest dedicated medical aesthetics business, is pleased to announce that BELOTERO® Balance has received EU approval for two additional indications: the treatment of infraorbital hollow (including the tear trough) and horizontal forehead lines1*. “With these new approvals, BELOTERO® Balance further strengthens its position as a versatile hyaluronic acid dermal filler, with a wide range of approved facial indications1 designed to integrate seamlessly within the skin and deliver predictable, harmonious aesthetic outcomes,” said Dr. Kerstin Olsson, Head of Medical Affairs EMEA. The approval of these two new indications is supported by compelling clinical evidence: In a clinical investigation on infraorbital hollow, 98.9% of subjects demonstrated visible improvement at Week 8, with long-lasting results sustained up to 72 weeks, and no treatment related serious adverse events reported.2 Similarly, in a postmarket investigation on horizontal forehead lines, 82.
Klarna Payments Now Available at B-Parts, Europe's Largest Automotive Parts Website30.3.2026 21:51:00 CEST | Press release
B-Parts is now offering its customers a more personalised and flexible shopping experience, with interest-free payments via "Pay in 3", amongst other Klarna features. Klarna, the global digital bank and flexible payments provider, is joining forces with B-Parts, a leading online retailer of used and original car parts, to offer consumers greater flexibility, convenience, choice and control at the point of payments, with no interest or hidden fees. Through Klarna’s interest-free installment payments, B-Parts customers will benefit from greater flexibility and control over their finances. Klarna also ensures a secure shopping experience thanks to its buyer protection scheme, as well as a range of features such as cashback and deals. "We continue to grow locally, with an increasing number of brands across different sectors recognising the enormous advantage of offering their customers more payment options, those that make for a more convenient and seamless checkout experience," explains I
Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings & Gatbits IT Infrastructure Announce Launch of GTBS Digital Ecosystem; Mainnet Set for April 202630.3.2026 20:30:00 CEST | Press release
The Office of His Highness Sheikh Hamdan Bin Ahmed Al Maktoum Holdings, in collaboration with Gatbits IT Infrastructure, has officially announced the launch of the GTBS Digital Ecosystem, marking a significant step forward in the global Web3 space. The announcement follows the successful launch of the native GTBS Coin on December 25, with the ecosystem’s mainnet scheduled to go live in April 2026. GTBS represents a full-stack Web3 ecosystem integrating blockchain, artificial intelligence, decentralized finance (DeFi), entertainment, gaming, media, and cloud infrastructure into a unified platform. Built on the philosophy of “All Commitment On Time,” the ecosystem focuses on delivering reliability, scalability, and real-world utility. Designed as a comprehensive digital infrastructure, GTBS goes beyond standalone crypto platforms by offering an integrated environment for users, developers, creators, and enterprises. Its proprietary Layer-1 blockchain powers seamless interaction across se
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom